Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby (), Leon Peto, Natalie Staplin, Mark Campbell, Guilherme Pessoa-Amorim, Marion Mafham, Jonathan R. Emberson, Richard Stewart, Benjamin Prudon, Alison Uriel, Christopher A. Green, Devesh J. Dhasmana, Flora Malein, Jaydip Majumdar, Paul Collini, Jack Shurmer, Bryan Yates, J. Kenneth Baillie, Maya H. Buch, Jeremy Day, Saul N. Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Richard Haynes and Martin J. Landray
Additional contact information
Peter W. Horby: University of Oxford
Leon Peto: University of Oxford
Natalie Staplin: University of Oxford
Mark Campbell: University of Oxford
Guilherme Pessoa-Amorim: University of Oxford
Marion Mafham: University of Oxford
Jonathan R. Emberson: University of Oxford
Richard Stewart: Milton Keynes University Hospital NHS Foundation Trust
Benjamin Prudon: North Tees and Hartlepool NHS Foundation Trust
Alison Uriel: Manchester University NHS Foundation Trust
Christopher A. Green: University Hospitals Birmingham NHS Foundation Trust
Devesh J. Dhasmana: Victoria Hospital Kirkcaldy, NHS Fife
Flora Malein: Liverpool University Hospitals NHS Foundation Trust
Jaydip Majumdar: Mid Cheshire Hospitals NHS Foundation Trust
Paul Collini: Sheffield Teaching Hospitals NHS Foundation Trust
Jack Shurmer: Bolton NHS Foundation Trust
Bryan Yates: Northumbria Healthcare NHS Foundation Trust
J. Kenneth Baillie: University of Edinburgh
Maya H. Buch: University of Manchester
Jeremy Day: Nuffield Department of Medicine, University of Oxford
Saul N. Faust: University Hospital Southampton NHS Foundation Trust and University of Southampton
Thomas Jaki: University of Regensburg
Katie Jeffery: Oxford University Hospitals NHS Foundation Trust
Edmund Juszczak: University of Nottingham
Marian Knight: University of Oxford
Wei Shen Lim: University of Nottingham
Alan Montgomery: University of Nottingham
Andrew Mumford: University of Bristol
Kathryn Rowan: Intensive Care National Audit & Research Centre
Guy Thwaites: Nuffield Department of Medicine, University of Oxford
Richard Haynes: University of Oxford
Martin J. Landray: University of Oxford

Nature Communications, 2024, vol. 15, issue 1, 1-13

Abstract: Abstract Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-43644-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-023-43644-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-43644-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().